[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pmv Pharmaceuticals Inc (PMVP)

Pmv Pharmaceuticals Inc (PMVP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 60,265
  • Shares Outstanding, K 53,332
  • Annual Sales, $ 0 K
  • Annual Income, $ -77,740 K
  • EBIT $ -84 M
  • EBITDA $ -86 M
  • 60-Month Beta 1.36
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.69

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 49.90%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Expected Move (DTE 25) 0.0000 (0.00%)
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A
  • Expected Range 1.1300 to 1.1300

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.43
  • Number of Estimates 2
  • High Estimate $-0.38
  • Low Estimate $-0.48
  • Prior Year $-0.41
  • Growth Rate Est. (year over year) -4.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0350 +11.11%
on 06/11/26
1.3050 -11.88%
on 05/26/26
-0.1100 (-8.73%)
since 05/22/26
3-Month
1.0350 +11.11%
on 06/11/26
1.5200 -24.34%
on 05/12/26
-0.3200 (-21.77%)
since 03/20/26
52-Week
0.9642 +19.27%
on 07/01/25
1.8800 -38.83%
on 03/02/26
+0.0600 (+5.50%)
since 06/20/25

Most Recent Stories

More News
PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancer New England Journal of Medicine published first-in-human rezatapopt...

PMVP : 1.1400 (+0.88%)
PMV Pharmaceuticals Announces Board Chair Transition

PRINCETON, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development...

PMVP : 1.1400 (+0.88%)
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation Rezatapopt...

PMVP : 1.1400 (+0.88%)
New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors

PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development...

PMVP : 1.1400 (+0.88%)
PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights

Updated clinical results from Phase 2 pivotal portion of the PYNNACLE study evaluating rezatapopt featured in late-breaking oral presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular...

PMVP : 1.1400 (+0.88%)
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics  Confirmed responses observed in eight tumor types spanning...

PMVP : 1.1400 (+0.88%)
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harboring...

PMVP : 1.1400 (+0.88%)
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and...

PMVP : 1.1400 (+0.88%)
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

PMVP : 1.1400 (+0.88%)
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights

PMVP : 1.1400 (+0.88%)

Business Summary

PMV Pharmaceuticals Inc.is a precision oncology company. It engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations. PMV Pharmaceuticals Inc.is headquartered in Cranbury, New Jersey.

See More

Key Turning Points

3rd Resistance Point 1.2233
2nd Resistance Point 1.1867
1st Resistance Point 1.1583
Last Price 1.1400
1st Support Level 1.0933
2nd Support Level 1.0567
3rd Support Level 1.0283

See More

52-Week High 1.8800
Fibonacci 61.8% 1.5302
Fibonacci 50% 1.4221
Fibonacci 38.2% 1.3140
Last Price 1.1400
52-Week Low 0.9642

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.